Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics^[1]. Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential drug candidate for treating triple-negative breast cancer (TNBC)^[2]. In Vitro: Ziyuglycoside I (5-160 µM; 24 hours) reveals a marked anti-proliferation activity with an IC₅₀ value of 13.96 µM in MDA-MB-231 cells^[2].
Ziyuglycoside I (5-20 µM; 24 hours) induces MDA-MB-231 cell apoptosis by increasing the percentage of apoptotic cells from 2.43% to 44.76% at 20 µM^[2].
Ziyuglycoside I (5-20 µM; 24 hours) induces the cleavage of caspas-8, caspase-9, and caspase-3, up-regulates the pro-apoptotic protein Bax, and down-regulates anti-apoptotic protein Bal-2, dose-dependently reduces the level of mito-cyto c expression^[2].